Table 7.

Amastigotes antigens in immunoblottings, revealed by 80–100% sera, from patients with active CL, after clinical remission, and healthy controls.

Antigens (kDa) revealed by sera from patients with CL and controls (patients)a
Active (10)				Remission (10)				Control IDR− (7)
La	Lb	Lv	Lch	La	Lb	Lv	Lch	La	Lb	Lv	Lch
22***	17*	22***	35***	22***	22***	33*	33*	17	17*	29	33*
33*	22***	33*	40***	33*	35***	35***	50*	33*	29*	33*	45
35***	29*	35***	50*	35***	40***	50*	65*	45	33*	45	50*
40***	33*	40***	57*	40***	50*	74*	74*	50*	45	50*	57*
50*	35***	50*	74*	50*	65*	80**	86**	57*	50*	65*	65*
57*	40***	65*	80***	57*	74***	90*	90***	65*	65*	74*	74*
65*	50*	74*	86*	65*	98***	98*	98*	86	90*	86	86*
74***	57***	80***	90***	74***	104***		104***	90	96	90*	98*
80***	65*		98*	100**	108**			98*	128	98*
98*	74***		104***					128*	132
100***	80***		128**
104***	86***
128*	90*
132**	98***
	100***
	104***
	115**
Total number of antigens in immunoblottings
La	Lb	Lv	Lch	La	Lb	Lv	Lch	La	Lb	Lv	Lch
Active lesions				Clinical remission				Healthy controls
14	17	8	11	9	9	7	8	10	10	9	8

^aCommon bands present in each Leishmania species in active, or remission and control IDR− groups^(∗). MW bands revealed by sera from active and clinical remission in same patients, not found by sera from controls at the respective homologous Leishmania specie^(∗∗∗). Specific antigens found in one leishmania specie only in active or remission group, respectively^(∗∗).